Ccl2 Protein (also known as MCP-1 - Monocyte Chemoattractant Protein-1) is a key chemokine that plays a central role in neuroinflammation and is critically implicated in the pathogenesis of multiple neurodegenerative diseases. This page provides comprehensive information about its structure, function, signaling mechanisms, and therapeutic targeting in neurodegeneration.
title: CCL2 Protein
description: MCP-1/CCL2 Chemokine - Key mediator of neuroinflammation in AD, PD, ALS
| Protein Name | MCP-1 / CCL2 Chemokine |
| Gene | CCL2 |
| UniProt ID | P13500 |
| PDB ID | 1DOK, 1DL9, 1BO0 |
| Molecular Weight | 11 kDa (monomer), 25 kDa (dimer) |
| Amino Acids | 99 (precursor), 76 (mature) |
| Subcellular Localization | Secreted, extracellular |
| Protein Family | CC chemokine family (C-C motif) |
| Receptor | CCR2, CCR4, CCR5 (alternatively) |
CCL2 (MCP-1) is a key CC chemokine that functions as a potent chemoattractant for monocytes, memory T lymphocytes, and dendritic cells. In the central nervous system (CNS), CCL2 is produced by astrocytes, microglia, neurons, and endothelial cells in response to injury, infection, or disease. The CCL2/CCR2 signaling axis is a major therapeutic target for modulating neuroinflammation in neurodegenerative disorders.
CCL2 is synthesized as a 99-amino acid precursor protein that undergoes proteolytic processing to generate a 76-residue mature secreted form. The protein contains:
The three-dimensional structure of CCL2 consists of:
The monomeric form is biologically active, but CCL2 can also form dimers at higher concentrations, which may have distinct receptor binding properties.
CCL2 binds primarily to CCR2 receptor on monocytes, memory T cells, and natural killer cells, inducing chemotaxis toward sites of inflammation. The signaling cascade involves:
In the healthy CNS, CCL2 plays important roles in:
While CCL2-mediated inflammation helps clear pathogens and cellular debris, chronic elevation contributes to neurotoxicity and progressive neuronal damage.
CCL2 is heavily implicated in Alzheimer's disease pathogenesis:
Key findings:
In Parkinson's disease, CCL2 contributes to dopaminergic neuron degeneration:
Key findings:
CCL2 plays a complex role in ALS:
Key findings:
In MS and its animal model EAE:
CCL2 is also implicated in:
CCL2 binds CCR2 (a G-protein coupled receptor), triggering multiple downstream pathways:
Gi/o protein pathways:
MAPK pathways:
Transcription factor activation:
CCL2 can also signal through:
Multiple CCR2 antagonists have been developed:
CCL2 has biomarker potential in neurodegeneration:
Polymorphisms in the CCL2 gene affect disease risk:
CCL2 is a critical chemokine that bridges peripheral immunity and neuroinflammation. While essential for normal immune surveillance and repair, chronic overexpression drives pathological neuroinflammation in AD, PD, ALS, and MS. The CCL2/CCR2 axis remains a promising but challenging therapeutic target, requiring careful modulation to achieve neuroprotection without compromising essential immune functions.
The study of Ccl2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313-326. PMID:19441883.
Baiocchi S, Bortolotto V, Grimaldi M, Cabib S. CCL2/MCP-1 in Alzheimer's disease and Parkinson's disease: therapeutic strategies. Neurobiol Dis. 2020;145:105077. PMID:32745892.
Conductier G, Blondeau N, Guyon A, Nahon JL, Rovira C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol. 2010;224(1-2):93-100. PMID:20663429.
Semple BD, Kossmann T, Morganti-Kossmann MC. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab. 2010;30(3):459-473. PMID:19904286.
Rostène W, Kitabgi P, Parsadaniantz SM. Chemokines: a new class of neuromodulators? Nat Rev Neurosci. 2007;8(11):895-903. PMID:17965655.
Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases. Mol Med Rep. 2016;13(4):3391-3396. PMID:26986132.
Kempuraj D, Thangavel R, Natteru PA, et al. Neuroinflammation induced by Aβ1-42 is mediated via IL-1β/IL-1R1 signaling in microglia. Neurochem Int. 2016;95:64-74. PMID:26921475.
Muzio L, Viotti A, Martino G. Microglia in neuroinflammation and neurodegeneration: from understanding to therapy. Neuroscientist. 2021;27(4):361-375. PMID:33012243.